Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

OBJECTIVE: To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland. METHODS: In this semi-Markov model, subcutaneous (SC) secukinumab was compared with SC treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Purmonen, Timo, Puolakka, Kari, Bhattacharyya, Devarshi, Jain, Minal, Martikainen, Janne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240184/
https://www.ncbi.nlm.nih.gov/pubmed/30479574
http://dx.doi.org/10.1186/s12962-018-0162-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240184/
https://www.ncbi.nlm.nih.gov/pubmed/30479574
http://dx.doi.org/10.1186/s12962-018-0162-3

Ejemplares similares